The recall of the Duloxetine Delayed-Release Capsules, produced by Towa Pharmaceutical Europe, was initiated on October 10 and has been given the second highest risk classification by the FDA.
For MDD, duloxetine may be a useful alternative for patients who do not benefit from or are unable to tolerate other antidepressant therapy. Conclusion: Duloxetine has been approved for the ...
Results that may be inaccessible to you are currently showing.